A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate (Q67672607)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1698754%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

title

A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1698754%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

1 November 2022

author name string

A. G. Meek

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698754

1 November 2022

T. L. Park

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698754

1 November 2022

E. Oberman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698754

1 November 2022

L. Wielopolski

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1698754

1 November 2022

language of work or name

English

0 references

publication date

1 September 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1698754%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

16 September 2019

https://api.elsevier.com/content/article/PII:036030169090504D?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

https://api.elsevier.com/content/article/PII:036030169090504D?httpAccept=text/plain

1 November 2022

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

International Journal of Radiation Oncology Biology Physics

1 November 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1698754%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1698754%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1698754%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

page(s)

733-741

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1698754%20AND%20SRC:MED&resulttype=core&format=json

Status of radiation treatment of prostate cancer at Stanford University

16 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Acid phosphatase, alkaline phosphatase and prostate specific antigen: which markers should we choose?

1 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Do prostatic biopsies 12 months or more after external irradiation for adenocarcinoma, Stage III, predict long-term survival?

1 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Is prostate-specific antigen the most useful marker for screening in prostate cancer?

1 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase

1 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice

1 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Prostate-specific antigen

1 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

1 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Use of human prostate-specific antigen in monitoring prostate cancer

1 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

1 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Prognostic significance of the pattern of tumor regression following definitive radiotherapy for carcinoma of the prostate

1 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Evaluation of prostate-specific antigen in prostate cancer

1 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers

1 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate

1 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients

1 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients

1 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

1 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

1 November 2022

23

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

Purification of a human prostate specific antigen

1 November 2022

26

1 reference

https://api.crossref.org/works/10.1016/0360-3016(90)90504-D

1 November 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1698754%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

1 reference